Evaluating diagnostic performance: A comparative analysis of cell-free DNA and serological test in hepatic cystic Echinococcosis

被引:0
|
作者
Orsten, S. [1 ,2 ]
Baysal, I. [1 ,2 ]
Sarikaya, M. [2 ]
Yagmur, E. [3 ]
Bozkurt, O. [4 ]
Karahan, S. [5 ]
Unal, E. [6 ]
Ciftci, S. Y. [2 ,7 ]
Dogrul, A. B. [8 ]
Akinci, D. [6 ]
Ciftci, T. [6 ]
Ergin, A. [1 ]
Akhan, O. [6 ]
机构
[1] Hacettepe Univ, Vocat Sch Hlth Serv, Ankara, Turkiye
[2] Hacettepe Univ, Grad Sch Hlth Sci, Dept One Hlth, Ankara, Turkiye
[3] Kahramanmaras Sutcu Imam Univ, Inst Hlth Sci, Dept Med Biochem, Kahramanmaras, Turkiye
[4] Kahramanmaras Sutcu Imam Univ, Inst Sci & Technol, Dept Biol, Kahramanmaras, Turkiye
[5] Hacettepe Univ, Fac Med, Dept Biostat, Ankara, Turkiye
[6] Hacettepe Univ, Fac Med, Dept Radiol, Ankara, Turkiye
[7] Hacettepe Univ, Fac Pharm, Dept Biochem, Ankara, Turkiye
[8] Hacettepe Univ, Fac Med, Dept Gen Surg, Ankara, Turkiye
关键词
<italic>Echinococcus granulosus</italic>; cystic echinococcosis; cell-free DNA; serology; biomarker; GRANULOSUS; BLOOD; TOOL;
D O I
10.1017/S0022149X24000853
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Cystic Echinococcosis (CE) is a zoonotic disease caused by Echinococcus granulosus sensu lato. Diagnosing CE primarily relies on imaging techniques, and there is a crucial need for an objective laboratory test to enhance the diagnostic process. Today, cell-free DNAs (cfDNAs) have gained importance regarding their biomarker potential. This study aims to investigate the diagnostic capabilities of different cfDNA targets (Echinococcus-specific repeat sequences (mgs-4 and mgs-12) and partial fragment of repetitive sequence (EG1 Hae III)) and evaluate their diagnostic effectiveness when compared to a frequently used commercial E.granulosus-specific IgG ELISA. Seventy-six confirmed hepatic CE patients and healthy controls were included in the study. The EG1 Hae III region was assessed using nested PCR, whereas real-time PCR was employed to investigate other cfDNA targets. Analysis of the cfDNA-targeted tests indicated that mgs-4 demonstrated the highest diagnostic efficacy in distinguishing CE patients from healthy controls, achieving a sensitivity of 60.5% (p = 0.002). Combining ELISA with the mgs-4 target led to an increased sensitivity of 72.4% for distinguishing between CE patients and the control group. The sensitivity rates for ELISA and the three cfDNA targets varied among the groups. Active CE patients showed sensitivity rates of 52.9%, 52.9%, 23.5%, and 52.9% for ELISA, mgs-4, mgs-12, and EG1 Hae III assays, respectively. In contrast, inactive cyst patients displayed sensitivity rates of 21.4%, 66.7%, 19%, and 42.9% for the corresponding assays. The mgs-4, either alone or in combination with ELISA, demonstrated notably higher sensitivity values for CE diagnosis in all group comparisons compared to serology.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] A FEASIBILITY STUDY EVALUATING THE USE OF CELL-FREE DNA ANALYSIS IN LABORATORY BRAIN CANCER INVESTIGATIONS
    Ganderton, Ros
    Monck, Chantelle
    Wojdacz, Tomasz
    Slevin, Mark
    Meakin, Nicola
    Grundy, Paul
    NEURO-ONCOLOGY, 2021, 23 : 25 - 25
  • [42] Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis
    Yigit, Buket
    Boyle, Marie
    Ozler, Oguz
    Erden, Nihan
    Tutucu, Faik
    Hardy, Timothy
    Bergmann, Christina
    Distler, Joerg H. W.
    Adali, Gupse
    Dayangac, Murat
    Mann, Derek A.
    Zeybel, Mujdat
    Mann, Jelena
    GUT, 2018, 67 (10) : 1906 - +
  • [43] Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer
    Driescher, Caroline
    Fuchs, Katharina
    Haeberle, Lena
    Goering, Wolfgang
    Frohn, Lisa
    Opitz, Friederike V.
    Haeussinger, Dieter
    Knoefel, Wolfram Trudo
    Keitel, Verena
    Esposito, Irene
    CANCERS, 2021, 13 (01) : 1 - 12
  • [44] Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis
    Yu, Dandan
    Tong, Yan
    Guo, Xinnian
    Feng, Lingfang
    Jiang, Zhaoqiang
    Ying, Shibo
    Jia, Junlin
    Fang, Yuan
    Yu, Min
    Xia, Hailing
    Shi, Li
    Lou, Jianlin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [45] Cell-free DNA in blood and urine as a diagnostic tool for bladder cancer: a meta-analysis
    Wang, Xin-Shuai
    Zhao, Meng-Qi
    Zhang, Li
    Kong, De-Jiu
    Ding, Xue-Zhen
    Hu, Xiao-Chen
    Yang, Jun-Qiang
    Gao, She-Gan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (07): : 1935 - 1948
  • [46] Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis
    Hou, Fei
    Sun, Xiao-Dan
    Deng, Zhi-Yong
    MEDICINE, 2023, 102 (07) : E32928
  • [47] Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Fotiou, Despoina
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (11): : E905 - E909
  • [48] The price of abandoning diagnostic testing for cell-free fetal DNA screening
    Evans, Mark I.
    Evans, Shara M.
    Bennett, Terry Ann
    Wapner, Ronald J.
    PRENATAL DIAGNOSIS, 2018, 38 (04) : 243 - 245
  • [49] Changing Face of Invasive Diagnostic Testing in the Era of Cell-Free DNA
    Al-Ibraheemi, Zainab
    Rosenn, Barak
    Porat, Natalie
    Taylor, Dyese
    Kalberer, Meredith
    Nelson, Zoe
    AMERICAN JOURNAL OF PERINATOLOGY, 2017, 34 (11) : 1142 - 1147
  • [50] Prenatal diagnostic testing trends in the era of cell-free DNA screening
    McElwee, Eliza R.
    Arruda, Elizabeth A.
    Shine, Kayla
    Lee, Jamison
    Newman, Roger
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2024, 230 (01) : S77 - S77